Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information



Addressing GLP Formulation Needs for Novel Compounds

Captisol® is a proven solubilizing technology designed to overcome various formulation challenges. Captisol® may enable increased systemic exposure for toxicology studies of investigative compounds and has a proven safety record.


Captisol® is a cyclic sugar with a large hydrophobic cavity and a hydrophilic exterior. The hydrophobic core weakly associates with a large range of compounds. Captisol® and the investigative compound form a complex that results in greatly enhanced aqueous solubility. 

Formulation and Toxicokinetics

Captisol® formulations are suitable for both parenteral and non-parenteral routes of administration. 

Nonclinical Safety

Captisol® is a modified cyclodextrin specifically designed for safety. Captisol® has been extensively characterized in acute and chronic GLP toxicology studies. A large database characterizing Captisol® effects in numerous species have been assembled and updated annually.

Regulatory Acceptance

Captisol® has an excellent clinical safety record and is currently being used as an excipient in multiple FDA approved prescription drugs (Nexterone®, Abilify®, Kyprolis®, Geodon®, VFend®). Captisol® enabled products have been approved in more than 50 countries. Captisol® formulation in early development can lead to a seamless transition from nonclinical safety to clinical trials.